Stacey Williamson, PA
Physician Assistant · Tigard, ORNPI 1457667891
Payments from drug & device makers
Across 226 payments — averaging $16.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$803
- Lilly USA, LLC$367
- Dexcom, Inc.$356
- AstraZeneca$228
- Mannkind Corporation$191
- Xeris Pharmaceuticals, Inc.$167
- plus $2K from 35 others
What the payments were for
- Food & beverage$3,75698%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 68 | $803 |
| Lilly USA, LLC | 17 | $367 |
| Dexcom, Inc. | 21 | $356 |
| AstraZeneca(2 entities) | 13 | $228 |
| Mannkind Corporation | 9 | $191 |
| Xeris Pharmaceuticals, Inc. | 8 | $167 |
| Medtronic | 8 | $165 |
| Sanofi-aventis U.S. LLC | 7 | $157 |
| Corcept Therapeutics | 5 | $127 |
| UCB, Inc. | 5 | $119 |
| Novartis | 6 | $117 |
| Bayer | 6 | $98 |
| Insulet Corporation | 3 | $71 |
| BETA Bionics, Inc. | 5 | $53 |
| Boehringer Ingelheim | 3 | $52 |
| Amgen | 3 | $50 |
| Ascensia Diabetes Care US Inc. | 2 | $43 |
| Intuity Medical Inc | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $40 |
| BD | 3 | $40 |
| Acadia Pharmaceuticals Inc | 2 | $39 |
| Radius Health, Inc. | 2 | $39 |
| EMD Serono, Inc. | 2 | $39 |
| Johnson & Johnson | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $34 |
| Lundbeck LLC | 2 | $33 |
| GE HealthCare | 2 | $32 |
| Verity Pharmaceuticals Inc. | 1 | $32 |
| Kyowa Kirin, Inc. | 2 | $31 |
| IBSA Pharma Inc. | 2 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Antares Pharma, Inc. | 1 | $19 |
| Argenx US, Inc. | 1 | $19 |
| Neurelis, Inc. | 1 | $16 |
| Merck | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Sequel Med Tech, LLC | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| SK Life Science, Inc. | 1 | $14 |
| AbbVie | 1 | $12 |
How this compares
$3,816 in reported general payments places this provider in the 95th percentile of 1,756 physician assistant providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 207 | $338,128 |
| MounjaroTirzepatide | 135 | $186,442 |
| FarxigaDapagliflozin Propanediol | 62 | $71,447 |
| JardianceEmpagliflozin | 34 | $50,703 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 50 | $49,075 |
| TrulicityDulaglutide | 32 | $42,142 |
| RybelsusSemaglutide | 26 | $39,962 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 16 | $37,601 |
| Humulin R U-500Insulin Regular, Human | 22 | $33,362 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $30,932 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $27,277 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $24,682 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 17 | $22,037 |
| JanuviaSitagliptin Phosphate | 11 | $18,053 |
| TradjentaLinagliptin | 17 | $17,622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $803 | $384,683256 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $367 | $237,073212 claims |
| AstraZenecaFarxiga | $228 | $71,44762 claims |
| Boehringer IngelheimJardiance, Tradjenta | $52 | $68,32551 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $157 | $27,27720 claims |
| MerckJanuvia | $15 | $18,05311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,756 physician assistant providers in Oregon.
Other physician assistant in Tigard
- Bradley StiefelTigard$7K
- Emily GeyenTigard$7K
- Sarah DanielTigard$6K
- Devon ParksEugene$62K
- Ryan CainCorvallis$55K
- Sean BrownPortland$43K
- Pooja PatelWoodburn$41K
- Meegan MangumPortland$25K
- Scott FrazeePortland$24K
- Marissa ReenEugene$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.